HHHiromichi Hemmi

Hiromichi Hemmi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiromichi Hemmi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Kanae Yamada

    Department of Molecular Biology, Toho University Faculty of Medicine, Tokyo 143-8540, Japan

    4 shared publications
  • Minoru Koi

    Gastrointestinal Cancer Research Laboratory, Baylor Research Institute and Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA

    4 shared publications
  • Junichi Koike

    Department of Surgery, Toho University School of Medicine, Tokyo 143-8541, Japan

    3 shared publications
  • Michitsune Arita

    Department of Molecular Biology, Toho University School of Medicine, Tokyo 143-8540, Japan

    3 shared publications
  • C. Richard Boland

    Gastrointestinal Cancer Research Laboratory, Baylor Research Institute and Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA

    2 shared publications
  • Hisahiko Sugiyama

    Toho Univ, Fac Med, Dept Surg, Tokyo 1438541, Japan

    2 shared publications

Latest Publications

  • Open Access

    Licochalcone A Inhibits BDNF and TrkB Gene Expression and Hypoxic Growth of Human Tumor Cell Lines

    by Michitsune Arita, Junichi Koike, Nobuji Yoshikawa, Motonari Kondo, Hiromichi Hemmi

    Hypoxic cellular proliferation is a common feature of tumor cells and is associated with tumor progression. Therefore, the inhibition of hypoxic cellular proliferation is expected to regulate malignancy processes. Licochalcone A (LicA) is known to show inhibitory effects on cell growth in normoxia, but it is unclear whether LicA exerts similar effects in hypoxia. Here, we studied the inhibitory activity of LicA in the hypoxic cellular proliferation of tumor cells and its molecular mechanism using human cell lines derived from various tumors including neuroblastoma and colorectal cancer. LicA inhibited cell growth at a 50% inhibitory concentration between 7.0 and 31.1 µM in hypoxia. LicA significantly suppressed hypoxic induction of tropomyosin receptor kinase B (TrkB) gene expression at the transcription level. LicA also downregulated mRNA levels of the TrkB high-affinity ligand brain-derived neurotrophic factor, but not neurotrophin-4, another TrkB ligand, or glyceraldehyde-3-phosphate dehydrogenase, indicating that the inhibitory activity of LicA is selective. Since both LicA-treatment and TrkB-knockdown decreased activation of protein kinase B in hypoxia, LicA exerts its inhibitory effect against hypoxic cell growth through inhibition of the TrkB-AKT axis. These results suggest that LicA has therapeutic potential for malignant tumors including neuroblastoma and colorectal cancer.


  • Down-regulation of MutS homolog 3 by hypoxia in human colorectal cancer

    by Jie Li, Junichi Koike, Hiroyuki Kugoh, Michitsune Arita, Takahito Ohhira, Yoshinori Kikuchi, Kimihiko Funahashi, Ken Takamatsu, C. Richard Boland, Minoru Koi, et al.


  • Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan

    by Hiromichi Hemmi, Kanae Yamada, Shinsaku Kanazawa, Junichi Koike, Hisahiko Sugiyama, Can Xu, Kimihiko Funahashi, C. Richard Boland, Minoru Koi

    Most tumors of patients with Lynch syndrome and a fraction of sporadic colorectal cancers (CRCs) exhibit high levels of microsatellite instability (MSI) at mono- and dinucleotide repeat loci. A different type of instability, elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) has been found in non-colonic cancers. Our previous study demonstrated that EMAST is common in sporadic CRC. Here, we focused on the relationships between EMAST and other genomic instability parameters or clinicopathological features in an unselected series of 88 sporadic CRCs. Of the tumors in the sample, 4 (4.5%) were MSI-high (MSI-H), 9 (10.2%) were MSI-low (MSI-L) and 75 (85.2%) were microsatellite stable. EMAST status was determined using 7 EMAST markers. Fifty-three (60.2%) tumors without MSI-H showed instability at ≥1 EMAST loci. All 4 MSI-H tumors showed instability at several EMAST loci. Instability profiles of MSI-H tumors at EMAST loci were more complex than those of non-MSI-H tumors. A tendency of positive association was observed between MSI-L and EMAST (P=0.023). The frequency of loss of heterozygosity (LOH) for the 14 loci in EMAST-positive tumors was significantly higher than negative tumors (P=0.048). Among the clinicopathological parameters, only tumor location at the distal colon was associated with EMAST-negative tumors (P=0.0084, one-tailed). A relatively higher frequency of well-differentiated adenocarcinomas was observed in EMAST tumors as opposed to non-EMAST tumors, though the survival rate was similar. These results suggest that overlapping mechanisms that cause MSI-L, EMAST and LOH in CRCs may exist.


    • 1 June 2009
      • Vol. 29  (6) , 2009-14

    14-3-3sigma-dependent resistance to cisplatin.

    by Zhiyong Han, Konstantinos Dimas, Xuefei Tian, Yongbao Wang, Hiromichi Hemmi, Kanae Yamada, Naoyuki Kato, Panayotis Pantazis, Rama J Ramanujam, Shrikant Anant, et al.

    A major factor that impedes the clinical success of cisplatin-based chemotherapy for cancer is cisplatin resistance by cancer cells. The sensitivity of parental HCT116 human colon cancer cell line and its isogenic gene-knockout sub-lines to cisplatin was determined by clonogenicity assay; furthermore, p53 activation, p21 expression, cell cycle arrest and senescence in these cells after cisplatin treatment were investigated. Parental cells were six times more resistant than 14-3-3sigma-knockout (sigma-KO) cells to cisplatin. Moreover, activation of p53, p53-dependent expression of p21 and p21-dependent senescence were observed in sigma-KO, but not parental cells after a treatment with a low cisplatin dose. A 14-3-3sigma-dependent mechanism inhibits p53 activation in parental cells treated with a low cisplatin dose, thereby blocking p21 expression that is essential for senescence and consequently conferring to the parental cells a significant degree of resistance to cisplatin.


  • A Single Nucleotide Substitution (−107C → G) in the hMLH1 Promoter Found in Colorectal Cancer Population Reduces Transcriptional Activity

    by Xiaoling Zhong, Michitsune Arita, Kanae Yamada, Hisahiko Sugiyama, Ke Tan, Shinsaku Kanazawa, Junichi Koike, Tatsuo Teramoto, Hiromichi Hemmi

    Inactivation of the DNA mismatch repair gene hMLH1 predisposes one to colorectal cancer. We have identified a C to G nucleotide substitution at position –107 relative to the hMLH1 gene translation initiation site in three of 163 colorectal cancer patients with an allele frequency of 0.0092 (3/326). One of the three −107G alleles occurred in one patient out of five with reduced hMLH1 expression in the tumor tissue. The −107G was not found in 63 healthy individuals. This substitution reduced transcriptional activity by 51% compared with −107C (P < 0.01) and impeded the promoter-binding capacity of nuclear proteins. Although the small number of identified −107G alleles is insufficient to evaluate the contribution to the carcinogenesis and clinicopathological properties of the tumors, the effects of −107G on hMLH1 gene transcription and nuclear protein binding to the promoter sequence implicate the site, including −107C, as a crucial element interacting with the activator that maintains hMLH1 gene expression.


  • One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes

    by Kanae Yamada, Naoyuki Kato, Akimitsu Takagi, Minoru Koi, Hiromichi Hemmi

    Platinum (Pt)–DNA adducts formed by the anti-tumor agent cisplatin are recognized by the DNA mismatch repair (MMR) system. To investigate the involvement of MMR proteins including hMLH1 in the removal of these adducts, we developed a mL-scale wet-digestion method for inductively coupled plasma mass spectrometry (ICP-MS). The detection limit was 0.01 ng mL−1 Pt, which corresponded to 2 pg Pt/μg DNA when 10 μg of DNA was used. The mean relative errors were 5.4% or better for a dynamic range of 0.01–10 ng mL−1 Pt. DNA (~500 μg) had no matrix effect. To improve the accuracy, DNA preparations were treated with ribonuclease and the apparent reduction in the concentration of Pt was corrected using cellular DNA levels, which were determined with Hoechst 33258. No significant differences were observed, in terms of the formation of Pt–DNA adducts or their removal over 6 h, between hMLH1-deficient HCT116 cells, a human colorectal cancer cell line, and hMLH1-complemented HCT116+ch3 cells (n=5; P>0.05), indicating that the hMLH1-dependent DNA repair systems contribute to neither the formation nor the removal of the adducts at detectable levels. In addition, approximately 19% of the adducts were removed within 6 h in both cell lines. A time course analysis (~24 h) suggested that the removal of cisplatin-generated Pt–DNA adducts follows first-order kinetics (t1/2=32 h). The amount of Pt–DNA adduct formed by oxaliplatin in 1 h was 56% (ratio of means) of that generated by an equimolar concentration of cisplatin in HCT116. The proposed procedure could be useful for determining Pt–DNA adducts formed by Pt(II) complexes.


  • Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors

    by Tomonori Takahashi, Zhenghua Min, Iichiro Uchida, Michitsune Arita, Yoh Watanabe, Minoru Koi, Hiromichi Hemmi